Advanced search
Publication Cover
Upsala Journal of Medical Sciences Volume 120, 2015 - Issue 1
Journal homepage
731
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

Predictors of liver failure in primary biliary cirrhosis

Pan ZhaoClinical Trial Center, Beijing 302 Hospital (PLA 302 Hospital), Beijing 100039, China;Liver Failure Therapy and Research Center, Beijing 302 Hospital (PLA 302 Hospital), Beijing 100039, China
,
Wei-wei LiuPostgraduate Division, Academy of Military Medical Science, Beijing 100850, China
,
Jin-feng LiRadiology Department, PLA General Hospital, Beijing 100853, China
,
Chun-ya WangEmergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
,
Hao WangMedical Information Center, Beijing 302 Hospital (PLA 302 Hospital), Beijing 100039, China
,
Jun XuClinical Laboratory, Beijing 302 Hospital (PLA 302 Hospital), Beijing 100039, China
,
Rui-fang WangUltrasonography Department, Beijing 302 Hospital (PLA 302 Hospital), Beijing 100039, China
,
Hao-zhen YangLiver Failure Therapy and Research Center, Beijing 302 Hospital (PLA 302 Hospital), Beijing 100039, China
,
Cheng JinClinical Trial Center, Beijing 302 Hospital (PLA 302 Hospital), Beijing 100039, China
&
Zhen-man WeiClinical Trial Center, Beijing 302 Hospital (PLA 302 Hospital), Beijing 100039, ChinaCorrespondence[email protected]
 show all
Pages 47-51 | Received 21 May 2014, Accepted 04 Nov 2014, Published online: 28 Nov 2014

References

  • Czul F, Peyton A, Levy C. Primary biliary cirrhosis: therapeutic advances. Clin Liver Dis. 2013;17:229–42.
  • Balmer ML, Dufour JF. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med Wkly. 2008;138:415–19.
  • Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology. 2010;52:349–59.
  • Zhao P, Han Y. Low incidence of positive smooth muscle antibody and high incidence of isolated IgM elevation in Chinese patients with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome: a retrospective study. BMC Gastrol. 2012;12:1.
  • Uibo R, Kisand K, Yang CY, Gershwin ME. Primary biliary cirrhosis: a multi-faced interactive disease involving genetics, environment and the immune response. APMIS. 2012;120:857–71.
  • Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12:CD000551.
  • Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, Nakamura M. Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Intern Med. 2011;50:1–10.
  • Qin B, Liang Y, Yang Z, Zhong R. Scientific publications on primary biliary cirrhosis from 2000 through 2010: an 11-year survey of the literature. PLoS One. 2012;7:e35366.
  • Karlsson-Parra A, Nyberg A, Tötterman TH, Lööf L, Forsum U. Primary biliary cirrhosis–phenotypic characterization of immunocompetent cells in peripheral blood and liver tissue. Ups J Med Sci. 1984;89:254–65.
  • Zhao P, Yang HZ, Li JF, Wang CY, Liu XY, Zhong YW, et al. A case of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome treated with Chinese herbs. Chin J Integr Med. 2013;19:468–70.
  • Liberal R, Grant CR, Sakkas L, Bizzaro N, Bogdanos DP. Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clin Res Hepatol Gastroenterol. 2013;37:572–85.
  • Chong VH, Telisinghe PU, Jalihal A. Primary biliary cirrhosis in Brunei Darussalam. Hepatobiliary Pancreat Dis Int. 2010;9:622–8.
  • Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51:265–9.
  • Alempijevic T, Sokic-Milutinovic A, Pavlovic Markovic A, Jesic-Vukicevic R, Milicic B, Macut D, et al. Assessment of metabolic syndrome in patients with primary biliary cirrhosis. Wien Klin Wochenschr. 2012;124:251–5.
  • Cash WJ, O’Neill S, O’Donnell ME, McCance DR, Young IS, McEneny J, et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int. 2013;33:1166–74.
  • Dilger K, Hohenester S, Winkler-Budenhofer U, Bastiaansen BA, Schaap FG, Rust C, et al. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol. 2012;57:133–40.
  • Inamine T, Higa S, Noguchi F, Kondo S, Omagari K, Yatsuhashi H, et al. Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol. 2013;48:1160–70.
  • Shi TY, Zhang LN, Chen H, Wang L, Shen M, Zhang X, et al. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis. World J Gastroenterol. 2013;19:1111–18.
  • Gatselis NK, Zachou K, Norman GL, Gabeta S, Papamichalis P, Koukoulis GK, et al. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 2013;46:471–9.
  • Bogdanos DP, Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta. 2011;412:502–12.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.